Meeting
2012 ASCO Annual Meeting
Phase I trial of pegylated liposomal doxorubicin and lapatinib in the treatment of metastatic breast cancer (MBC): Final results.
Authors
Mary E. Cianfrocca
Banner M. D. Anderson Cancer Center, Gilbert, AZ
Mary E. Cianfrocca , Virginia G. Kaklamani , Steven T. Rosen , Jamie H. Von Roenn , Alfred Rademaker , Deborah A. Smith , Stephen D. Rubin , Caitlin Meservey , Regina Uthe , William John Gradishar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00316875
Citation
J Clin Oncol 30, 2012 (suppl; abstr 610)
DOI
10.1200/jco.2012.30.15_suppl.610
Abstract #
610
Poster Bd #
10E
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer.
First Author: Andrea Rocca
Poster
2015 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of non-pegylated liposome-encapsulated doxorubicin citrate (NPLD) plus carboplatin in patients with recurrent gynecological and primary peritoneal tumors.
First Author: Andres Poveda
Poster
2012 ASCO Annual Meeting
Phase I trial of ixabepilone and vorinostat in metastatic breast cancer.
First Author: Thehang H. Luu
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens